The first injectable implant containing polymethylmethacrylate (PMMA) microspheres was developed in Germany more than 20 years ago. Continuous studies and improvements have resulted in the third and current generation with Linnea Safe brand being one of the most prominent. The first generation initiated in Germany in the 90s proved to be effective, although it caused some adverse reactions. Most of these reactions were caused by nodules in the injection sites, occasionally associated with the inflammatory response. Further investigations led to the conclusion that there is a specific limit to the diameter of PMMA microspheres, which is essential to avoid adverse reactions. The investigations and scientific literature published from these studies suggest that PMMA microspheres, less than 20 µ in diameter, can trigger a foreign body reaction.
Brazilian manufacturer Lebon pharmaceuticals with its product Linnea Safe incorporated the lessons learned during these two decades and, using a patented technology called Uniform Microsphere Smooth Surface (UMSS) accurately obtains total round and smooth microspheres with a diameter of 40 micra (abbreviated as µm which is the millionth part of a meter).
Linnea Safe PMMA is laboratory synthesized using differentiated technologies and following strict safety protocols and tests, as determined by the scientific literature and ANVISA (the Brazilian FDA) standards.